Health and Healthcare
AbbVie, Eli Lilly, Gilead, and More Biopharma Stocks Reporting Earnings This Week
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week. Health care has been a big winner in the wake of the coronavirus, and the sector has largely outpaced the markets. These earnings will help dictate where the sector goes from here.
Note that the earnings and revenue estimates may change ahead of the formal reports, and some companies may reschedule reporting dates as well. Also see our separate previews for technology, Dow Jones industrials and other major companies reporting earnings this week.
Amgen Inc. (NASDAQ: AMGN) is set to report its most recent results on Tuesday afternoon. The consensus estimates from Refinitiv call for earnings per share (EPS) of $3.82 and $6.18 billion in revenue. Shares were changing hands at $247.98 on Friday’s close. The 52-week range is $173.12 to $264.97.
Sanofi S.A. (NASDAQ: SNY) will share its latest quarterly earnings Wednesday morning. The consensus estimates call for breakeven earnings on $9.89 billion in revenue. Shares traded at $51.15 on Friday’s close, in a 52-week range of $37.62 to $55.00. The consensus price target is $59.00.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is scheduled to report its second-quarter results on Thursday before the opening bell. The consensus estimates are $2.58 in EPS and $1.28 billion in revenue. Shares traded at $101.49 as last week came to a close. The consensus price target is $138.42, and the 52-week trading range is $72.67 to $125.52.
Eli Lilly and Co. (NYSE: LLY) is expected to reveal its second-quarter results on Thursday morning. The consensus forecast calls for $1.56 in EPS, as well as $5.76 billion in revenue. The stock ended last week at $159.54 per share. The consensus price target is $162.93, and the 52-week range is $101.36 to $170.75.
AstraZeneca PLC (NYSE: AZN) also will share its latest quarterly earnings first thing Thursday as well. The consensus estimates call for $0.44 in EPS and $6.28 billion in revenue. Shares were at $55.80 as Friday’s trading ended, in a 52-week range of $36.15 to $64.94. The consensus price target is $56.65.
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is scheduled to report its second-quarter results on Thursday afternoon. The consensus forecast calls for $2.07 in EPS, as well as $1.39 billion in revenue. The stock ended last week at $278.49 per share. The consensus price target is $295.91, and the 52-week range is $165.23 to $306.08.
Gilead Sciences Inc. (NASDAQ: GILD) is expected to reveal its second-quarter results on Thursday after the close. The consensus forecast calls for $1.48 in EPS, as well as $5.34 billion in revenue. The stock closed at $73.64 per share. The consensus price target is $81.42, and the 52-week trading range is $60.89 to $85.97.
And AbbVie Inc. (NYSE: ABBV) will post its latest quarterly earnings on Friday morning. The consensus estimates call for $2.19 in EPS and $10.07 billion in revenue. Shares were at $97.11 as Friday’s trading ended, in a 52-week range of $62.55 to $101.28. The consensus price target is $104.69.
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.